Skip to main content
. 2011 Dec 29;22(4):589–597. doi: 10.1007/s10165-011-0557-x

Fig. 3.

Fig. 3

a Mean serum adalimumab (ADA) concentrations by visit in Japanese patients with ankylosing spondylitis (AS) receiving adalimumab 40 mg every other week with [+ standard deviation (SD)] and without (−SD) concomitant methotrexate (MTX) therapya; b serum adalimumab concentrations by visit in Japanese patients (n = 6) receiving adalimumab 40 mg every other week, with dose escalation to 80 mg every other week